A Contract Development and Manufacturing Organization (CDMO) that specializes in sterile injectables focuses on the development and manufacturing of injectable drugs in a sterile environment. These organizations typically offer services ranging from formulation development to final sterile fill and finish. They adhere to strict regulatory standards to ensure the safety, efficacy, and quality of the injectable products they produce. Sterile injectables are crucial for various medical applications, including intravenous, intramuscular, and subcutaneous administration of medications. A CDMO specializing in this area plays a vital role in bringing these essential pharmaceutical products to market.
The global Sterile Injectable CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Sterile Injectable CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sterile Injectable CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Sterile Injectable CDMO in Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Sterile Injectable CDMO include Abbvie, Famar, Polfa Tarchomin, Pfizer, Quotient Sciences, Temad Co., Tianjin Hankang Pharmaceutical Biotechnology, Fareva, Sharp, Astral SteriTech, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Sterile Injectable CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sterile Injectable CDMO.
The Sterile Injectable CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sterile Injectable CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sterile Injectable CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbvie
Famar
Polfa Tarchomin
Pfizer
Quotient Sciences
Temad Co.
Tianjin Hankang Pharmaceutical Biotechnology
Fareva
Sharp
Astral SteriTech
Evonik
Aurigene Pharmaceutical Services
Prague Scientific
Ethypharm
TriRx Pharmaceutical Services
Biophrama Group
Gensenta Pharmaceuticals
BioTechnique
Mithra CDMo
S.C. Rompharm Company SRL
Flagship Biotech International Pvt. Ltd
Curida AS
BirgiMefar Group
Brooks Laboratories Limited
Segment by Type
Preclinical Manufacturing
Clinical Manufacturing
Commercial Manufacturing
Segment by Application
Pharmaceutical Company
Research Institute
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sterile Injectable CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sterile Injectable CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Preclinical Manufacturing
1.2.3 Clinical Manufacturing
1.2.4 Commercial Manufacturing
1.3 Market by Application
1.3.1 Global Sterile Injectable CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Company
1.3.3 Research Institute
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sterile Injectable CDMO Market Perspective (2019-2030)
2.2 Global Sterile Injectable CDMO Growth Trends by Region
2.2.1 Global Sterile Injectable CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sterile Injectable CDMO Historic Market Size by Region (2019-2024)
2.2.3 Sterile Injectable CDMO Forecasted Market Size by Region (2025-2030)
2.3 Sterile Injectable CDMO Market Dynamics
2.3.1 Sterile Injectable CDMO Industry Trends
2.3.2 Sterile Injectable CDMO Market Drivers
2.3.3 Sterile Injectable CDMO Market Challenges
2.3.4 Sterile Injectable CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sterile Injectable CDMO Players by Revenue
3.1.1 Global Top Sterile Injectable CDMO Players by Revenue (2019-2024)
3.1.2 Global Sterile Injectable CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Sterile Injectable CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Sterile Injectable CDMO Revenue
3.4 Global Sterile Injectable CDMO Market Concentration Ratio
3.4.1 Global Sterile Injectable CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sterile Injectable CDMO Revenue in 2023
3.5 Global Key Players of Sterile Injectable CDMO Head office and Area Served
3.6 Global Key Players of Sterile Injectable CDMO, Product and Application
3.7 Global Key Players of Sterile Injectable CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Sterile Injectable CDMO Breakdown Data by Type
4.1 Global Sterile Injectable CDMO Historic Market Size by Type (2019-2024)
4.2 Global Sterile Injectable CDMO Forecasted Market Size by Type (2025-2030)
5 Sterile Injectable CDMO Breakdown Data by Application
5.1 Global Sterile Injectable CDMO Historic Market Size by Application (2019-2024)
5.2 Global Sterile Injectable CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Sterile Injectable CDMO Market Size (2019-2030)
6.2 North America Sterile Injectable CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Sterile Injectable CDMO Market Size by Country (2019-2024)
6.4 North America Sterile Injectable CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sterile Injectable CDMO Market Size (2019-2030)
7.2 Europe Sterile Injectable CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Sterile Injectable CDMO Market Size by Country (2019-2024)
7.4 Europe Sterile Injectable CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sterile Injectable CDMO Market Size (2019-2030)
8.2 Asia-Pacific Sterile Injectable CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Sterile Injectable CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Sterile Injectable CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sterile Injectable CDMO Market Size (2019-2030)
9.2 Latin America Sterile Injectable CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Sterile Injectable CDMO Market Size by Country (2019-2024)
9.4 Latin America Sterile Injectable CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sterile Injectable CDMO Market Size (2019-2030)
10.2 Middle East & Africa Sterile Injectable CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Sterile Injectable CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Sterile Injectable CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Details
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Sterile Injectable CDMO Introduction
11.1.4 Abbvie Revenue in Sterile Injectable CDMO Business (2019-2024)
11.1.5 Abbvie Recent Development
11.2 Famar
11.2.1 Famar Company Details
11.2.2 Famar Business Overview
11.2.3 Famar Sterile Injectable CDMO Introduction
11.2.4 Famar Revenue in Sterile Injectable CDMO Business (2019-2024)
11.2.5 Famar Recent Development
11.3 Polfa Tarchomin
11.3.1 Polfa Tarchomin Company Details
11.3.2 Polfa Tarchomin Business Overview
11.3.3 Polfa Tarchomin Sterile Injectable CDMO Introduction
11.3.4 Polfa Tarchomin Revenue in Sterile Injectable CDMO Business (2019-2024)
11.3.5 Polfa Tarchomin Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Sterile Injectable CDMO Introduction
11.4.4 Pfizer Revenue in Sterile Injectable CDMO Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Quotient Sciences
11.5.1 Quotient Sciences Company Details
11.5.2 Quotient Sciences Business Overview
11.5.3 Quotient Sciences Sterile Injectable CDMO Introduction
11.5.4 Quotient Sciences Revenue in Sterile Injectable CDMO Business (2019-2024)
11.5.5 Quotient Sciences Recent Development
11.6 Temad Co.
11.6.1 Temad Co. Company Details
11.6.2 Temad Co. Business Overview
11.6.3 Temad Co. Sterile Injectable CDMO Introduction
11.6.4 Temad Co. Revenue in Sterile Injectable CDMO Business (2019-2024)
11.6.5 Temad Co. Recent Development
11.7 Tianjin Hankang Pharmaceutical Biotechnology
11.7.1 Tianjin Hankang Pharmaceutical Biotechnology Company Details
11.7.2 Tianjin Hankang Pharmaceutical Biotechnology Business Overview
11.7.3 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Introduction
11.7.4 Tianjin Hankang Pharmaceutical Biotechnology Revenue in Sterile Injectable CDMO Business (2019-2024)
11.7.5 Tianjin Hankang Pharmaceutical Biotechnology Recent Development
11.8 Fareva
11.8.1 Fareva Company Details
11.8.2 Fareva Business Overview
11.8.3 Fareva Sterile Injectable CDMO Introduction
11.8.4 Fareva Revenue in Sterile Injectable CDMO Business (2019-2024)
11.8.5 Fareva Recent Development
11.9 Sharp
11.9.1 Sharp Company Details
11.9.2 Sharp Business Overview
11.9.3 Sharp Sterile Injectable CDMO Introduction
11.9.4 Sharp Revenue in Sterile Injectable CDMO Business (2019-2024)
11.9.5 Sharp Recent Development
11.10 Astral SteriTech
11.10.1 Astral SteriTech Company Details
11.10.2 Astral SteriTech Business Overview
11.10.3 Astral SteriTech Sterile Injectable CDMO Introduction
11.10.4 Astral SteriTech Revenue in Sterile Injectable CDMO Business (2019-2024)
11.10.5 Astral SteriTech Recent Development
11.11 Evonik
11.11.1 Evonik Company Details
11.11.2 Evonik Business Overview
11.11.3 Evonik Sterile Injectable CDMO Introduction
11.11.4 Evonik Revenue in Sterile Injectable CDMO Business (2019-2024)
11.11.5 Evonik Recent Development
11.12 Aurigene Pharmaceutical Services
11.12.1 Aurigene Pharmaceutical Services Company Details
11.12.2 Aurigene Pharmaceutical Services Business Overview
11.12.3 Aurigene Pharmaceutical Services Sterile Injectable CDMO Introduction
11.12.4 Aurigene Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2019-2024)
11.12.5 Aurigene Pharmaceutical Services Recent Development
11.13 Prague Scientific
11.13.1 Prague Scientific Company Details
11.13.2 Prague Scientific Business Overview
11.13.3 Prague Scientific Sterile Injectable CDMO Introduction
11.13.4 Prague Scientific Revenue in Sterile Injectable CDMO Business (2019-2024)
11.13.5 Prague Scientific Recent Development
11.14 Ethypharm
11.14.1 Ethypharm Company Details
11.14.2 Ethypharm Business Overview
11.14.3 Ethypharm Sterile Injectable CDMO Introduction
11.14.4 Ethypharm Revenue in Sterile Injectable CDMO Business (2019-2024)
11.14.5 Ethypharm Recent Development
11.15 TriRx Pharmaceutical Services
11.15.1 TriRx Pharmaceutical Services Company Details
11.15.2 TriRx Pharmaceutical Services Business Overview
11.15.3 TriRx Pharmaceutical Services Sterile Injectable CDMO Introduction
11.15.4 TriRx Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2019-2024)
11.15.5 TriRx Pharmaceutical Services Recent Development
11.16 Biophrama Group
11.16.1 Biophrama Group Company Details
11.16.2 Biophrama Group Business Overview
11.16.3 Biophrama Group Sterile Injectable CDMO Introduction
11.16.4 Biophrama Group Revenue in Sterile Injectable CDMO Business (2019-2024)
11.16.5 Biophrama Group Recent Development
11.17 Gensenta Pharmaceuticals
11.17.1 Gensenta Pharmaceuticals Company Details
11.17.2 Gensenta Pharmaceuticals Business Overview
11.17.3 Gensenta Pharmaceuticals Sterile Injectable CDMO Introduction
11.17.4 Gensenta Pharmaceuticals Revenue in Sterile Injectable CDMO Business (2019-2024)
11.17.5 Gensenta Pharmaceuticals Recent Development
11.18 BioTechnique
11.18.1 BioTechnique Company Details
11.18.2 BioTechnique Business Overview
11.18.3 BioTechnique Sterile Injectable CDMO Introduction
11.18.4 BioTechnique Revenue in Sterile Injectable CDMO Business (2019-2024)
11.18.5 BioTechnique Recent Development
11.19 Mithra CDMo
11.19.1 Mithra CDMo Company Details
11.19.2 Mithra CDMo Business Overview
11.19.3 Mithra CDMo Sterile Injectable CDMO Introduction
11.19.4 Mithra CDMo Revenue in Sterile Injectable CDMO Business (2019-2024)
11.19.5 Mithra CDMo Recent Development
11.20 S.C. Rompharm Company SRL
11.20.1 S.C. Rompharm Company SRL Company Details
11.20.2 S.C. Rompharm Company SRL Business Overview
11.20.3 S.C. Rompharm Company SRL Sterile Injectable CDMO Introduction
11.20.4 S.C. Rompharm Company SRL Revenue in Sterile Injectable CDMO Business (2019-2024)
11.20.5 S.C. Rompharm Company SRL Recent Development
11.21 Flagship Biotech International Pvt. Ltd
11.21.1 Flagship Biotech International Pvt. Ltd Company Details
11.21.2 Flagship Biotech International Pvt. Ltd Business Overview
11.21.3 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Introduction
11.21.4 Flagship Biotech International Pvt. Ltd Revenue in Sterile Injectable CDMO Business (2019-2024)
11.21.5 Flagship Biotech International Pvt. Ltd Recent Development
11.22 Curida AS
11.22.1 Curida AS Company Details
11.22.2 Curida AS Business Overview
11.22.3 Curida AS Sterile Injectable CDMO Introduction
11.22.4 Curida AS Revenue in Sterile Injectable CDMO Business (2019-2024)
11.22.5 Curida AS Recent Development
11.23 BirgiMefar Group
11.23.1 BirgiMefar Group Company Details
11.23.2 BirgiMefar Group Business Overview
11.23.3 BirgiMefar Group Sterile Injectable CDMO Introduction
11.23.4 BirgiMefar Group Revenue in Sterile Injectable CDMO Business (2019-2024)
11.23.5 BirgiMefar Group Recent Development
11.24 Brooks Laboratories Limited
11.24.1 Brooks Laboratories Limited Company Details
11.24.2 Brooks Laboratories Limited Business Overview
11.24.3 Brooks Laboratories Limited Sterile Injectable CDMO Introduction
11.24.4 Brooks Laboratories Limited Revenue in Sterile Injectable CDMO Business (2019-2024)
11.24.5 Brooks Laboratories Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Abbvie
Famar
Polfa Tarchomin
Pfizer
Quotient Sciences
Temad Co.
Tianjin Hankang Pharmaceutical Biotechnology
Fareva
Sharp
Astral SteriTech
Evonik
Aurigene Pharmaceutical Services
Prague Scientific
Ethypharm
TriRx Pharmaceutical Services
Biophrama Group
Gensenta Pharmaceuticals
BioTechnique
Mithra CDMo
S.C. Rompharm Company SRL
Flagship Biotech International Pvt. Ltd
Curida AS
BirgiMefar Group
Brooks Laboratories Limited
听
听
*If Applicable.
